Heron Therapeutics is trading up 10.25% at $0.39 on October 9, 2026, with no direct company-specific catalyst identified. - The supplied context reports XBI up 2.50%, providing a positive biotech-sector backdrop; available evidence does not establish it as the direct cause of the gain. - The latest listed company release is its August 10 second-quarter results.